Literature DB >> 35342811

Author Reply to "Intravenous thrombolysis in patients taking direct oral anticoagulants (European stroke organisation intravenous thrombolysis guidelines comment).

Gian Marco De Marchis1, Guillaume Turc2,3,4, William Whiteley5, Georgios Tsivgoulis6,7.   

Abstract

Entities:  

Year:  2021        PMID: 35342811      PMCID: PMC8948517          DOI: 10.1177/23969873211058566

Source DB:  PubMed          Journal:  Eur Stroke J        ISSN: 2396-9873


× No keyword cloud information.
  13 in total

1.  Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.

Authors:  Stuart J Connolly; Mark Crowther; John W Eikelboom; C Michael Gibson; John T Curnutte; John H Lawrence; Patrick Yue; Michele D Bronson; Genmin Lu; Pamela B Conley; Peter Verhamme; Jeannot Schmidt; Saskia Middeldorp; Alexander T Cohen; Jan Beyer-Westendorf; Pierre Albaladejo; Jose Lopez-Sendon; Andrew M Demchuk; Daniel J Pallin; Mauricio Concha; Shelly Goodman; Janet Leeds; Sonia Souza; Deborah M Siegal; Elena Zotova; Brandi Meeks; Sadia Ahmad; Juliet Nakamya; Truman J Milling
Journal:  N Engl J Med       Date:  2019-02-07       Impact factor: 91.245

2.  Monitoring of low dabigatran concentrations: diagnostic performance at clinically relevant decision thresholds.

Authors:  Florian Härtig; Sven Poli; Matthias Ebner; Ingvild Birschmann; Joachim Kuhn; Ulf Ziemann; Hans-Ulrich Häring; Rainer Lehmann; Andreas Peter; Sebastian Hörber
Journal:  J Thromb Thrombolysis       Date:  2020-04       Impact factor: 2.300

3.  Coagulation Testing in Acute Ischemic Stroke Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants.

Authors:  Jan C Purrucker; Kirsten Haas; Timolaos Rizos; Shujah Khan; Sven Poli; Peter Kraft; Christoph Kleinschnitz; Rainer Dziewas; Andreas Binder; Frederick Palm; Sebastian Jander; Hassan Soda; Peter U Heuschmann; Roland Veltkamp
Journal:  Stroke       Date:  2016-11-29       Impact factor: 7.914

4.  Modeling the Clinical Implications of Andexanet Alfa in Factor Xa Inhibitor-Associated Intracerebral Hemorrhage.

Authors:  Carlin C Chuck; Daniel Kim; Roshini Kalagara; Nathaniel Rex; Tracy E Madsen; Leana Mahmoud; Bradford B Thompson; Richard N Jones; Karen L Furie; Michael E Reznik
Journal:  Neurology       Date:  2021-09-23       Impact factor: 11.800

5.  Feasibility of rapid measurement of Rivaroxaban plasma levels in patients with acute stroke.

Authors:  David J Seiffge; Christopher Traenka; Alexandros Polymeris; Lisa Hert; Urs Fisch; Nils Peters; Gian Marco De Marchis; Raphael Guzman; Christian H Nickel; Philipp A Lyrer; Leo H Bonati; Dimitrios Tsakiris; Stefan Engelter
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

Review 6.  Testing and monitoring direct oral anticoagulants.

Authors:  Jean M Connors
Journal:  Blood       Date:  2018-09-10       Impact factor: 22.113

7.  Using an old test for new tricks: Measuring direct oral anti-Xa drug levels by conventional heparin-calibrated anti-Xa assay.

Authors:  Cheryl L Maier; William H Asbury; Alexander Duncan; Adele Robbins; Ann Ingle; Adam Webb; Sean R Stowell; John D Roback
Journal:  Am J Hematol       Date:  2019-02-21       Impact factor: 10.047

8.  Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study.

Authors:  Anne Godier; Anne-Sophie Dincq; Anne-Céline Martin; Adrian Radu; Isabelle Leblanc; Marion Antona; Marc Vasse; Jean-Louis Golmard; François Mullier; Isabelle Gouin-Thibault
Journal:  Eur Heart J       Date:  2017-08-14       Impact factor: 29.983

9.  European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke.

Authors:  Eivind Berge; William Whiteley; Heinrich Audebert; Gian Marco De Marchis; Ana Catarina Fonseca; Chiara Padiglioni; Natalia Pérez de la Ossa; Daniel Strbian; Georgios Tsivgoulis; Guillaume Turc
Journal:  Eur Stroke J       Date:  2021-02-19

10.  The Magic of Randomization versus the Myth of Real-World Evidence.

Authors:  Rory Collins; Louise Bowman; Martin Landray; Richard Peto
Journal:  N Engl J Med       Date:  2020-02-13       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.